2,4-diisopropyl-pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,4-diisopropyl-pyrimidine
• 英文别名: 2,4-Diisopropyl-pyrimidin；2,4-Di(propan-2-yl)pyrimidine
• 化学式: C₁₀H₁₆N₂
• 分子量: 164.25
• InChiKey: UUHJUJUUJHECOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  异丁腈 、 乙炔 在 氢化钾 作用下， 200.0 ℃ 、1.96 MPa 条件下， 生成 2,4-diisopropyl-pyrimidine
  参考文献：
  名称：

  gem-Dithiols¹

  摘要：

  DOI：

  10.1021/ja01136a004

文献信息

• Anti-Viral Compounds
  申请人：DeGoey David A.

  公开号：US20100317568A1

  公开（公告）日：2010-12-16

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法、包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。
• SOLUBLE GUANYLATE CYCLASE ACTIVATORS
  申请人：Bittner Amy R.

  公开号：US20090209556A1

  公开（公告）日：2009-08-20

  A compound having the structure useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.

  具有治疗或预防心血管疾病、内皮功能障碍、舒张功能障碍、动脉硬化、高血压、心绞痛、血栓形成、再狭窄、心肌梗死、中风、心脏衰竭、肺动脉高压、勃起功能障碍、支气管哮喘、慢性肾功能不全、糖尿病或人或动物患者肝硬化的化合物的结构。
• POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：CLARK Ryan

  公开号：US20110082164A1

  公开（公告）日：2011-04-07

  Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

  本文描述了一些作为赖氨酸磷脂酸受体拮抗剂的化合物。还描述了包括本文描述的化合物的药物组合物和药物，以及使用这些拮抗剂的方法，单独或与其他化合物结合，用于治疗依赖或介导赖氨酸磷脂酸的疾病或病症。
• BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL
  申请人：Kuo Gee-Hong

  公开号：US20070244094A1

  公开（公告）日：2007-10-18

  The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

  该发明涉及一种化合物，其化学式为（I），可用作PPAR激动剂。还描述了使用该发明的化合物治疗糖尿病、肾病、神经病、视网膜病变、多囊卵巢综合征、高血压、缺血、中风、肠易激综合征、炎症、白内障、心血管疾病、代谢X综合征、高LDL胆固醇血症、血脂异常（包括高甘油三酯血症、高胆固醇血症、混合性高脂血症和低HDL胆固醇血症）、动脉粥样硬化、肥胖以及其他与脂质代谢和能量稳态并发症相关的疾病的药物组合物和治疗方法。
• [EN] N-(5-(6-ETHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(METHYLSULFONAMIDO)PYRIMIDIN-4-YL) TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE N-(5-(6-ÉTHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(MÉTHYLSULFONAMIDO)PYRIMIDIN-4-YL) TÉTRAHYDRO-2H-PYRAN-4-CARBOXAMIDE ET DES COMPOSÉS APPARENTÉS SERVANT D'INHIBITEURS DE CTPS1 HUMAINS POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：STEP PHARMA S A S

  公开号：WO2020245664A1

  公开（公告）日：2020-12-10

  Compounds of formula (I) as human cytidine triphosphate synthase 1 ( CTPS1) inhibitors for the treatment of proliferative diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 64 to 80; examples; biological examples 1 and 2; e.g. compounds P140, P231 to P263; tables 1 to 10). Specific examples are e.g.: N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido) pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (Formula (II)), or 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6- ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (Formula (III)).

  化合物的化学式（I）作为人类胞嘧啶三磷酸合成酶1（CTPS1）抑制剂，用于治疗增殖性疾病，例如癌症，如白血病和淋巴瘤，例如炎症性皮肤病如牛皮癣，或多发性硬化症。本说明书披露了示例化合物的合成和表征，以及其药理学数据（例如，第64至80页；示例；生物学示例1和2；例如，化合物P140，P231至P263；表1至10）。具体示例包括：N-(5-(6-乙氧基吡嗪-2-基)吡啶-2-基)-4-(2-(甲磺酰胺基)嘧啶-4-基)四氢-2H-吡喃-4-羧酰胺（化学式（II）），或1-(2-(环丙磺酰胺基)嘧啶-4-基)-N-(5-(6-乙氧基吡嗪-2-基)吡啶-2-基)环己烷-1-羧酰胺（化学式（III））。